CL2010001159A1 - Compuestos derivados de 3,8-diazabiciclo[2.4.0]octano y 3,6-diazabiciclo[3.2.0]heptano disustituidos, moduladores del receptor de orexina; composicion farmaceutica; utiles en el tratamiento de trastornos del sueño, trastornos metabolicos, entre otros. - Google Patents
Compuestos derivados de 3,8-diazabiciclo[2.4.0]octano y 3,6-diazabiciclo[3.2.0]heptano disustituidos, moduladores del receptor de orexina; composicion farmaceutica; utiles en el tratamiento de trastornos del sueño, trastornos metabolicos, entre otros.Info
- Publication number
- CL2010001159A1 CL2010001159A1 CL2010001159A CL2010001159A CL2010001159A1 CL 2010001159 A1 CL2010001159 A1 CL 2010001159A1 CL 2010001159 A CL2010001159 A CL 2010001159A CL 2010001159 A CL2010001159 A CL 2010001159A CL 2010001159 A1 CL2010001159 A1 CL 2010001159A1
- Authority
- CL
- Chile
- Prior art keywords
- diazabicyclo
- disubstituted
- octane
- heptane
- useful
- Prior art date
Links
- XKEYAOJRNJYJMM-UHFFFAOYSA-N 3,6-diazabicyclo[3.2.0]heptane Chemical compound C1NCC2CNC21 XKEYAOJRNJYJMM-UHFFFAOYSA-N 0.000 title abstract 2
- KNLOUXALILBKPY-UHFFFAOYSA-N 5,8-diazabicyclo[4.2.0]octane Chemical compound C1CCNC2CNC21 KNLOUXALILBKPY-UHFFFAOYSA-N 0.000 title abstract 2
- 108050000742 Orexin Receptor Proteins 0.000 title abstract 2
- 102000008834 Orexin receptor Human genes 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000019116 sleep disease Diseases 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25452909P | 2009-10-23 | 2009-10-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2010001159A1 true CL2010001159A1 (es) | 2011-05-06 |
Family
ID=43430851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2010001159A CL2010001159A1 (es) | 2009-10-23 | 2010-10-22 | Compuestos derivados de 3,8-diazabiciclo[2.4.0]octano y 3,6-diazabiciclo[3.2.0]heptano disustituidos, moduladores del receptor de orexina; composicion farmaceutica; utiles en el tratamiento de trastornos del sueño, trastornos metabolicos, entre otros. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8680275B2 (enExample) |
| EP (1) | EP2491034B1 (enExample) |
| JP (1) | JP5847087B2 (enExample) |
| AR (1) | AR078733A1 (enExample) |
| CL (1) | CL2010001159A1 (enExample) |
| PE (1) | PE20110296A1 (enExample) |
| TW (1) | TW201121966A (enExample) |
| UY (1) | UY32968A (enExample) |
| WO (1) | WO2011050200A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012004753A (es) | 2009-10-23 | 2012-09-07 | Janssen Pharmaceutica Nv | Octahidropirrolo[3,4-c]pirrolos disustituidos como moduladores del receptor de orexina. |
| WO2012085857A1 (en) * | 2010-12-22 | 2012-06-28 | Actelion Pharmaceuticals Ltd | 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides |
| WO2013050938A1 (en) * | 2011-10-04 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives |
| ES2572703T3 (es) | 2011-11-08 | 2016-06-01 | Actelion Pharmaceuticals Ltd. | Derivados de 2-(1,2,3-triazol-2-il)benzamida y 3-(1,2,3-triazol-2-il)picolinamida como antagonistas del receptor de orexina |
| CA2863413A1 (en) | 2012-02-07 | 2013-08-15 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| CN104334544B (zh) | 2012-06-04 | 2016-10-19 | 埃科特莱茵药品有限公司 | 苯并咪唑脯氨酸衍生物 |
| MX2015004638A (es) | 2012-10-10 | 2015-07-14 | Actelion Pharmaceuticals Ltd | Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-) aril]-[2-meta bi-(hetero-) aril)-pirrolidin-1-il]-metanona. |
| CN103012293A (zh) * | 2012-12-13 | 2013-04-03 | 同济大学 | 一种抗失眠药物mk-4305中间体的合成方法 |
| US9550786B2 (en) * | 2013-01-16 | 2017-01-24 | Merck Sharp & Dohme Corp. | 4-fluoropiperidine orexin receptor antagonists |
| CN105051040A (zh) | 2013-03-12 | 2015-11-11 | 埃科特莱茵药品有限公司 | 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物 |
| TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
| TWI621618B (zh) * | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途 |
| TW201444821A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
| CA2917198C (en) * | 2013-07-10 | 2022-06-07 | Vertex Pharmaceuticals Incorporated | Fused piperidine amides as modulators of ion channels |
| CA2930053A1 (en) | 2013-12-04 | 2015-06-11 | Actelion Pharmaceuticals Ltd | Use of benzimidazole-proline derivatives |
| MX2016010745A (es) * | 2014-02-20 | 2017-02-02 | Takeda Pharmaceuticals Co | Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina. |
| EP3180332B1 (en) | 2014-08-13 | 2021-10-27 | Eolas Therapeutics Inc. | Difluoropyrrolidines as orexin receptor modulators |
| WO2016040789A1 (en) | 2014-09-11 | 2016-03-17 | Janssen Pharmaceutica Nv | Substituted 2-azabicycles and their use as orexin receptor modulators |
| US10000499B2 (en) | 2014-11-26 | 2018-06-19 | Merck Sharp & Dohme Corp. | Methyl diazepane orexin receptor antagonists |
| WO2016100157A2 (en) * | 2014-12-19 | 2016-06-23 | Merck Sharp & Dohme Corp. | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists |
| WO2016208602A1 (ja) | 2015-06-23 | 2016-12-29 | キッセイ薬品工業株式会社 | ピラゾール誘導体、またはその薬理学的に許容される塩 |
| AU2016295693B2 (en) | 2015-07-17 | 2020-05-21 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
| JP6936224B2 (ja) * | 2015-11-23 | 2021-09-15 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | オクタヒドロピロロ［３，４−ｃ］ピロール誘導体およびその使用 |
| EA036542B9 (ru) | 2016-02-12 | 2020-12-22 | Астразенека Аб | Галоген-замещенные пиперидины в качестве модуляторов орексинового рецептора |
| UA125873C2 (uk) | 2016-03-10 | 2022-06-29 | Янссен Фармацевтика Нв | Спосіб лікування депресії з використанням антагоністів рецептора орексин-2 |
| JP6654614B2 (ja) * | 2016-12-21 | 2020-02-26 | キッセイ薬品工業株式会社 | Ｔｒｐｍ８阻害薬 |
| EP3619199B1 (en) | 2017-05-03 | 2021-07-07 | Idorsia Pharmaceuticals Ltd | Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives |
| EP3668864B1 (en) | 2017-09-28 | 2021-07-21 | Boehringer Ingelheim International GmbH | N-(2,2-difluoroethyl)-n-[(pyrimidinylamino)propanyl]arylcarboxamides |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6375897B1 (en) | 2000-02-14 | 2002-04-23 | Ansys Technologies, Inc. | Urine collection cup |
| MY145722A (en) | 2000-04-27 | 2012-03-30 | Abbott Lab | Diazabicyclic central nervous system active agents |
| US6809105B2 (en) | 2000-04-27 | 2004-10-26 | Abbott Laboratories | Diazabicyclic central nervous system active agents |
| CN1549816A (zh) | 2001-06-28 | 2004-11-24 | ʷ | 作为阿立新受体拮抗药的n-芳酰基环胺衍生物 |
| US6455722B1 (en) | 2001-06-29 | 2002-09-24 | Pabu Services, Inc. | Process for the production of pentaerythritol phosphate alcohol |
| GB0130341D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| MXPA04002269A (es) | 2002-07-09 | 2004-06-29 | Actelion Pharmaceuticals Ltd | Derivados de 7,8,9,10-tetrahidro-6h-azepino,6,7,8,9-tetrahidro-pirido y 2,3-dihidro-2h-pirrolo[2,1-b]-quinazolinona. |
| DE60335891D1 (de) | 2002-10-11 | 2011-03-10 | Actelion Pharmaceuticals Ltd | Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste |
| GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| US20040242641A1 (en) * | 2003-05-27 | 2004-12-02 | Buckley Michael J. | (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent |
| US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
| US7399765B2 (en) | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| EP1846409A1 (en) | 2004-11-24 | 2007-10-24 | Pfizer Limited | Octahydropyrrolo[3,4-c]pyrrole derivatives |
| ZA200709626B (en) | 2005-05-13 | 2009-02-25 | Lexicon Pharmaceuticals Inc | Multicyclic compounds and methods of their use |
| WO2006124897A2 (en) | 2005-05-13 | 2006-11-23 | Lexicon Genetics Incorporated | Methods and compositions for improving cognition |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| JP2009506061A (ja) * | 2005-08-26 | 2009-02-12 | メルク エンド カムパニー インコーポレーテッド | ジアザスピロデカンオレキシン受容体拮抗薬 |
| WO2007126935A2 (en) | 2006-03-29 | 2007-11-08 | Merck & Co., Inc. | Diazepan orexin receptor antagonists |
| US20090105318A1 (en) | 2006-03-29 | 2009-04-23 | Coleman Paul J | Amidoethylthioether Orexin Receptor Antagonists |
| JP2009543790A (ja) | 2006-07-14 | 2009-12-10 | メルク エンド カムパニー インコーポレーテッド | ２−置換プロリンビス−アミドオレキシン受容体アンタゴニスト |
| EP2049529B1 (en) | 2006-07-14 | 2010-08-11 | Merck Sharp & Dohme Corp. | Substituted diazepan orexin receptor antagonists |
| AU2007272854B2 (en) * | 2006-07-14 | 2013-08-01 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
| ATE472549T1 (de) | 2006-09-18 | 2010-07-15 | Hoffmann La Roche | Octahydropyrroloä3,4-cüpyrrolderivate und ihre verwendung als antivirale mittel |
| US20080153811A1 (en) | 2006-11-07 | 2008-06-26 | Joseph Barbosa | Methods of Treating Cognitive Impairment and Dementia |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| WO2008143856A1 (en) | 2007-05-18 | 2008-11-27 | Merck & Co., Inc. | Oxo bridged diazepan orexin receptor antagonists |
| FR2918061B1 (fr) | 2007-06-28 | 2010-10-22 | Sanofi Aventis | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique. |
| FR2918986B1 (fr) | 2007-07-19 | 2009-09-04 | Sanofi Aventis Sa | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
| WO2009022311A2 (en) | 2007-08-15 | 2009-02-19 | Actelion Pharmaceuticals Ltd | 1,2-diamido-ethylene derivatives as orexin antagonists |
| CA2703904A1 (en) | 2007-10-29 | 2009-05-07 | Merck Sharp & Dohme Corp. | Substituted diazepan orexin receptor antagonists |
| BRPI0821676A2 (pt) | 2007-12-21 | 2015-06-16 | Astrazeneca Ab | Composto, composição farmacêutica, e, processo para a preparação dos compostos. |
| KR101204213B1 (ko) | 2007-12-21 | 2012-11-26 | 에프. 호프만-라 로슈 아게 | 오렉신 수용체 길항제로서의 헤테로아릴 유도체 |
| GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
| AR072899A1 (es) | 2008-08-07 | 2010-09-29 | Merck Sharp & Dohme | Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad. |
| US8129384B2 (en) | 2008-10-09 | 2012-03-06 | Glaxo Group Limited | Imidazo[1,2-a]pyrazines as orexin receptor antagonists |
| US8093255B2 (en) | 2008-10-09 | 2012-01-10 | Glaxo Group Limited | Imidazo[1,2-A]pyrimidines as orexin receptor antagonists |
| US8466281B2 (en) | 2008-10-21 | 2013-06-18 | Merck Sharp & Dohme Corp. | 2,5-disubstituted morpholine orexin receptor antagonists |
| US8669272B2 (en) | 2008-10-21 | 2014-03-11 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
| EP2349269A4 (en) | 2008-10-21 | 2012-04-25 | Merck Sharp & Dohme | 2,5-DISUBSTITUTED PIPERIDINOREXINE RECEPTOR ANTAGONISTS |
| EP2348856B1 (en) | 2008-10-21 | 2013-08-14 | Merck Sharp & Dohme Corp. | 2,4-disubstituted pyrrolidine orexin receptor antagonists |
| JP2012506379A (ja) | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 二置換アゼパンオレキシン受容体アンタゴニスト |
| JP2012507539A (ja) | 2008-10-30 | 2012-03-29 | メルク・シャープ・エンド・ドーム・コーポレイション | ２，５−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト |
| JP2012507540A (ja) | 2008-10-30 | 2012-03-29 | メルク・シャープ・エンド・ドーム・コーポレイション | ピリダジンカルボキサミド・オレキシン受容体アンタゴニスト |
| KR101320245B1 (ko) | 2008-10-30 | 2013-10-30 | 머크 샤프 앤드 돔 코포레이션 | 이소니코틴아미드 오렉신 수용체 길항제 |
| WO2010060472A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Imidazopyridazine derivatives acting as orexin antagonists |
| WO2010060471A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| EP2358711A1 (en) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| AU2009324239A1 (en) | 2008-12-02 | 2010-06-10 | Glaxo Group Limited | N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof |
| TW201031407A (en) | 2008-12-02 | 2010-09-01 | Glaxo Group Ltd | Novel compounds |
| GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
-
2010
- 2010-10-21 WO PCT/US2010/053609 patent/WO2011050200A1/en not_active Ceased
- 2010-10-21 US US13/503,312 patent/US8680275B2/en active Active
- 2010-10-21 JP JP2012535385A patent/JP5847087B2/ja not_active Expired - Fee Related
- 2010-10-21 EP EP10774359.3A patent/EP2491034B1/en active Active
- 2010-10-22 PE PE2010000999A patent/PE20110296A1/es not_active Application Discontinuation
- 2010-10-22 CL CL2010001159A patent/CL2010001159A1/es unknown
- 2010-10-22 TW TW099136020A patent/TW201121966A/zh unknown
- 2010-10-22 AR ARP100103876A patent/AR078733A1/es unknown
- 2010-10-25 UY UY0001032968A patent/UY32968A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UY32968A (es) | 2011-04-29 |
| JP5847087B2 (ja) | 2016-01-20 |
| AR078733A1 (es) | 2011-11-30 |
| US8680275B2 (en) | 2014-03-25 |
| EP2491034A1 (en) | 2012-08-29 |
| WO2011050200A1 (en) | 2011-04-28 |
| US20120202783A1 (en) | 2012-08-09 |
| TW201121966A (en) | 2011-07-01 |
| PE20110296A1 (es) | 2011-05-21 |
| EP2491034B1 (en) | 2013-12-18 |
| HK1175461A1 (en) | 2013-07-05 |
| JP2013508404A (ja) | 2013-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2010001159A1 (es) | Compuestos derivados de 3,8-diazabiciclo[2.4.0]octano y 3,6-diazabiciclo[3.2.0]heptano disustituidos, moduladores del receptor de orexina; composicion farmaceutica; utiles en el tratamiento de trastornos del sueño, trastornos metabolicos, entre otros. | |
| CL2010001160A1 (es) | Compuestos derivados de 3,8-diazabiciclo[4.2.0]octano y 3,6-diazabiciclo[3.2.0]heptano; composicion farmaceutica; moduladores del reeptor de la orexina, utiles en el tratamiento del insomnio. | |
| EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| NI201200062A (es) | Octahidropirrolo [3, 4-c] pirroles disustituidos | |
| CL2012001673A1 (es) | Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras. | |
| EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| CL2012003604A1 (es) | Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros. | |
| CL2008001197A1 (es) | Compuestos derivados de amidas sustituidas, moduladoras de la actividad de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome metabolico, resistencia a la insulina, dislipidemia, entre otras. | |
| CL2011000668A1 (es) | Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras. | |
| CL2008003593A1 (es) | Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer | |
| UY31619A1 (es) | Compuestos espiro como antagonistas del receptor npy y5 | |
| CL2008000434A1 (es) | Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros. | |
| TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
| CL2012003427A1 (es) | Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras. | |
| PL2134704T3 (pl) | Związki i kompozycje pełniące rolę modulatorów aktywności GPR119 | |
| CL2008001114A1 (es) | Compuestos derivados de bencimidazol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como vejiga sobreactiva, dolor, obesidad, convulsiones, entre otras. | |
| CL2011000488A1 (es) | Compuestos derivados de pirazolo-pirimidinas sustituidas; composicion y combinacion farmaceutica que los comprenden; y su uso como inhibidores de pde9 para el tratamiento, alivio y/o prevencion de deterioros cognitivos relacionados con la percepcion, alzheimer,trastornos del sueño, trastorno bipolar, diabetes mellitus. | |
| EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| CL2008003116A1 (es) | Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras. | |
| CL2008002268A1 (es) | Compuestos derivados de amidas, moduladores del receptor taar1; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, entre otros. | |
| CL2012001605A1 (es) | Compuestos derivados de quinolina-2-carboxamida, moduladores alostericos positivos del receptor muscarino m1; composicion farmaceutica que comprende al compuesto; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades tales como alzheimer, trastornos del dolor o del sueño. | |
| EA201100138A1 (ru) | 4-феноксиметилпиперидины в качестве модуляторов активности gpr119 | |
| CL2013002474A1 (es) | Compuestos derivados de piperidina puenteada (3-aza-biciclo[3.2.1]oct-8-il), moduladores de b-amiloide; procedimiento de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades tales como alzheimer, síndrome de down, entre otras. | |
| CL2011000043A1 (es) | Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central. | |
| CL2013003484A1 (es) | Compuestos derivados de n-(4-morfolin-2-il)fenil)-1h-pirazol-(3 o 5)-carboxamida o n-(4-piperidin-3-il)fenil)-1h-pirazol-(3 o 5)-carboxamida afines a receptores asociados a taar1; procedimiento de preparacion; composicion farmaceutica y uso en el tratamiento y/o la profilaxis de enfermedades tales como depresion, trastorno bipolar, alzheimer y parkinson, entre otras. |